TESARO is devoted to providing transformative therapies to people bravely facing cancer.

Our Corporate History

2017

ZEJULA (niraparib) Approved by FDA and Launched in the U.S.

VARUBY (rolapitant) and ZEJULA (niraparib) Approved in Europe

Development of Niraparib Expanded

Registration Trial for TSR-042 Initiated

Nirparib License Agreement with Takeda Announced

CEO Lonnie Moulder and President/COO Dr. Mary Lynne Hedley Named EY Entrepreneurs of the Year

2016

$155 Million Private Placement Completed

Rolapitant IV NDA Submitted to U.S. FDA

Rolapitant Oral MAA Submitted to EMA

Phase 1 Trials of TSR-042 and TSR-022 Initiated

Immuno-oncology Collaboration with MD Anderson Announced

Collaboration with Janssen in Prostate Cancer Began

Results of Phase 3 NOVA Trial of Niraparib Announced

$409 Million Follow-on Stock Offering Completed

Phase 3 Trial of Niraparib in 1st Line Ovarian Cancer Initiated (PRIMA)

$236 Million Follow-on Stock Offering Completed

Niraparib NDA Submitted to U.S. FDA

Niraparib MAA Submitted to EMA

2015

$192M Follow-on Stock Offering Completed

Collaboration with Merck Announced to Evaluate Niraparib in Combination with Pembrolizumab

First Product VARUBI® Oral (Rolapitant) Approved by FDA and launched in the U.S.

Rolapitant IV NDA Submitted to U.S. FDA

European Headquarters Opened in Zug, Switzerland

2014

$101M Follow-on Stock Offering Completed

Final Phase 3 Trial of Rolapitant Oral Completed

Niraparib Phase 3 Trial in Breast Cancer Initiated (BRAVO)

Rolapitant Oral NDA Submitted to U.S. FDA

$201M Convertible Debt Offering Completed

2013

$98M Follow-on Stock Offering Completed

First Phase 3 Trial of Niraparib in Ovarian Cancer Initiated (NOVA)

Rolapitant IV Clinical Program Initiated

Top-line Results of First Two Phase 3 Trials of Rolapitant Oral Announced

2012

Three Phase 3 Trials of Rolapitant Oral Initiated

Niraparib In-licensed

Initial Public Offering (NASDAQ: TSRO) Completed

2011

$101M Series B Financing Completed

2010

TESARO Founded

$20M Series A Financing Completed

Rolapitant In-licensed